Posted by Michael Wonder on 30 Dec 2020
BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List
27 December 2020 - Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor Brukinsa (zanubrutinib) are included in the National Reimbursement Drug List in a total of four approved indications.
BeiGene today announced that three of its innovative oncology medicines have been included in the updated National Reimbursement Drug List by the China National Healthcare Security Administration, including its internally-developed anti-PD-1 antibody tislelizumab, its internally-developed BTK inhibitor Brukinsa (zanubrutinib), and Xgeva (120 mg denosumab) from its strategic collaboration with Amgen.
